| Literature DB >> 36226158 |
Yiqing Shen1,2, Wensong Yang1,2, Xin Xiong3, Xinhui Li1,2, Zhongsong Xiao1,2, Jialun Yu1, Fangyu Liu1,2, Siwen Gui2, Xiongfei Xie4, Fajin Lv5, Libo Zhao6,7, Liangbo Hu4, Anatol Manaenko1,2, Peng Xie1,2, Qi Li1,2.
Abstract
Existing treatments for intracerebral hemorrhage (ICH) are unable to satisfactorily prevent development of secondary brain injury after ICH and multiple pathological mechanisms are involved in the development of the injury. In this study, we aimed to identify novel genes and proteins and integrated their molecular alternations to reveal key network modules involved in ICH pathology. A total of 30 C57BL/6 male mice were used for this study. The collagenase model of ICH was employed, 3 days after ICH animals were tested neurological. After it, animals were euthanized and perihematomal brain tissues were collected for transcriptome and TMT labeling-based quantitative proteome analyses. Protein-protein interaction (PPI) network, Gene Set Enrichment Analysis (GSEA), and regularized Canonical Correlation Analysis (rCCA) were performed to integrated multiomics data. For validation of hub genes and proteins, qRT-PCR and Western blot were carried out. The candidate biomarkers were further measured by ELISA in the plasma of ICH patients and the controls. A total of 2218 differentially expressed genes (DEGs) and 353 differentially expressed proteins (DEPs) between the ICH model group and control group were identified. GSEA revealed that immune-related gene sets were prominently upregulated and significantly enriched in pathways of inflammasome complex, negative regulation of interleukin-12 production, and pyroptosis during the ICH process. The rCCA network presented two highly connective clusters which were involved in the sphingolipid catabolic process and inflammatory response. Among ten hub genes screened out by integrative analysis, significantly upregulated Itgb2, Serpina3n, and Ctss were validated in the ICH group by qRT-PCR and Western blot. Plasma levels of human SERPINA3 (homologue of murine Serpina3n) were elevated in ICH patients compared with the healthy controls (SERPINA3: 13.3 ng/mL vs. 11.2 ng/mL, p = 0.015). Within the ICH group, higher plasma SERPINA3 levels with a predictive threshold of 14.31 ng/mL (sensitivity = 64.3%; specificity = 80.8%; AUC = 0.742, 95% CI: 0.567-0.916) were highly associated with poor outcome (mRS scores 4-6). Taken together, the results of our study exhibited molecular changes related to ICH-induced brain injury by multidimensional analysis and effectively identified three biomarker candidates in a mouse ICH model, as well as pointed out that Serpina3n/SERPINA3 was a potential biomarker associated with poor functional outcome in ICH patients.Entities:
Mesh:
Substances:
Year: 2021 PMID: 36226158 PMCID: PMC8691985 DOI: 10.1155/2021/2510847
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1The workflow of this study and histological evaluation of the ICH mouse model. (a) Overall workflow chart of this study. (b) Representative images of brain Section (1 mm thick) in the control group and ICH group. (c) HE staining of brain tissue of control mice and ICH mice. Low-magnification (×40) images show the overall hematoma area following ICH (black arrow), high-magnification (×100, ×400) images show the significant histopathological changes (green arrows). n = 4 per group. (d) Statistical analysis of modified Garcia test in the ICH group and control group 3 days after operation. (e) Statistical analysis of beam walking test in the ICH group and control group 3 days after operation. n = 16 per group. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
Figure 2Expression and functional enrichment analysis of DEGs following ICH. (a) Box plots of gene expression distribution between the ICH and control groups. (b) Heatmap of the correlation of gene expression levels between the ICH and control groups. (c) Two-dimensional PCA analysis between ICH and control samples. (d) Three-dimensional PCA analysis between ICH and control samples. (e) Volcano plots of 2218 DEGs among transcriptomic profile between the ICH and control groups. (f) Heatmap of hierarchical clustering analysis of 2218 DEGs between the ICH and control groups. (g) Top GO and KEGG pathways enriched by DEGs between the ICH and control groups. ICH group: mice with M1-M5; control group: mice with M9-M13.
GO and KEGG enrichment analysis of DEGs following ICH.
| Ontology | ID | Description | GeneRatio | BgRatio |
|
|
|
|---|---|---|---|---|---|---|---|
| BP | GO:0050900 | Leukocyte migration | 92/1311 | 340/23210 | 8.65 | 4.39 | 3.28 |
| BP | GO:0002274 | Myeloid leukocyte activation | 72/1311 | 215/23210 | 1.74 | 4.41 | 3.30 |
| BP | GO:0001819 | Positive regulation of cytokine production | 99/1311 | 449/23210 | 1.78 | 3.00 | 2.25 |
| BP | GO:0031349 | Positive regulation of defense response | 84/1311 | 370/23210 | 1.24 | 1.57 | 1.18 |
| BP | GO:0007159 | Leukocyte cell-cell adhesion | 77/1311 | 319/23210 | 3.46 | 3.52 | 2.63 |
| CC | GO:0062023 | Collagen-containing extracellular matrix | 59/1322 | 359/23436 | 1.17 | 4.20 | 3.56 |
| CC | GO:0031012 | Extracellular matrix | 70/1322 | 475/23436 | 1.57 | 4.20 | 3.56 |
| CC | GO:0000779 | Condensed chromosome, centromeric region | 20/1322 | 51/23436 | 1.34 | 2.16 | 1.83 |
| CC | GO:0000775 | Chromosome, centromeric region | 39/1322 | 190/23436 | 1.61 | 2.16 | 1.83 |
| CC | GO:0098687 | Chromosomal region | 49/1322 | 299/23436 | 1.58 | 1.70 | 1.44 |
| MF | GO:0008009 | Chemokine activity | 20/1278 | 44/22710 | 4.23 | 1.87 | 1.57 |
| MF | GO:0004896 | Cytokine receptor activity | 29/1278 | 97/22710 | 4.53 | 1.87 | 1.57 |
| MF | GO:0019955 | Cytokine binding | 32/1278 | 129/22710 | 6.89 | 1.89 | 1.59 |
| MF | GO:0005125 | Cytokine activity | 41/1278 | 215/22710 | 4.93 | 1.01 | 8.54 |
| MF | GO:0042379 | Chemokine receptor binding | 20/1278 | 67/22710 | 4.01 | 6.61 | 5.57 |
| KEGG | mmu04060 | Cytokine-cytokine receptor interaction | 70/582 | 302/8910 | 1.11 | 3.15 | 2.46 |
| KEGG | mmu04061 | Viral protein interaction with cytokine and cytokine receptor | 35/582 | 103/8910 | 7.27 | 1.03 | 8.03 |
| KEGG | mmu04640 | Hematopoietic cell lineage | 30/582 | 96/8910 | 1.58 | 1.49 | 1.16 |
| KEGG | mmu05152 | Tuberculosis | 41/582 | 180/8910 | 7.97 | 5.64 | 4.41 |
| KEGG | mmu05323 | Rheumatoid arthritis | 26/582 | 87/8910 | 2.12 | 1.20 | 9.37 |
Figure 3Expression and functional enrichment analysis of DEPs following ICH. (a) Volcano plots of 353 DEPs among proteomics profile between the ICH and control groups. (b) Heatmap of hierarchical clustering analysis of 353 DEPs between the ICH and control groups. (c) Top GO and KEGG pathways enriched by DEGs between the ICH and control group. ICH group: mice with M6-M8; control group: mice with M14-M16.
GO and KEGG enrichment analysis of DEPs following ICH.
| Ontology | ID | Description | GeneRatio | BgRatio |
|
|
|
|---|---|---|---|---|---|---|---|
| BP | GO:0007596 | Blood coagulation | 19/333 | 156/23210 | 1.18 | 2.12 | 1.50 |
| BP | GO:0007599 | Hemostasis | 19/333 | 158/23210 | 1.49 | 2.12 | 1.50 |
| BP | GO:0050817 | Coagulation | 19/333 | 159/23210 | 1.67 | 2.12 | 1.50 |
| BP | GO:0042060 | Wound healing | 27/333 | 360/23210 | 2.87 | 2.74 | 1.94 |
| BP | GO:0009611 | Response to wounding | 31/333 | 495/23210 | 7.37 | 5.63 | 3.98 |
| CC | GO:0062023 | Collagen-containing extracellular matrix | 29/339 | 359/23436 | 8.19 | 3.58 | 2.56 |
| CC | GO:0031012 | Extracellular matrix | 32/339 | 475/23436 | 5.96 | 1.30 | 9.31 |
| CC | GO:0015629 | Actin cytoskeleton | 23/339 | 490/23436 | 8.83 | 1.29 | 9.20 |
| CC | GO:0005764 | Lysosome | 21/339 | 431/23436 | 1.48 | 1.34 | 9.57 |
| CC | GO:0000323 | Lytic vacuole | 21/339 | 432/23436 | 1.53 | 1.34 | 9.57 |
| MF | GO:0003779 | Actin binding | 25/327 | 428/22710 | 3.77 | 2.39 | 1.96 |
| MF | GO:0004857 | Enzyme inhibitor activity | 22/327 | 384/22710 | 4.70 | 1.44 | 1.18 |
| MF | GO:0061135 | Endopeptidase regulator activity | 16/327 | 209/22710 | 6.80 | 1.44 | 1.18 |
| MF | GO:0061134 | Peptidase regulator activity | 17/327 | 244/22710 | 1.04 | 1.65 | 1.35 |
| MF | GO:0004867 | Serine-type endopeptidase inhibitor activity | 11/327 | 118/22710 | 1.13 | 1.44 | 1.18 |
| KEGG | mmu04610 | Complement and coagulation cascades | 15/169 | 93/8910 | 1.72 | 4.38 | 4.12 |
| KEGG | mmu04611 | Platelet activation | 10/169 | 124/8910 | 1.17 | 0.015 | 0.014 |
| KEGG | mmu04142 | Lysosome | 10/169 | 131/8910 | 1.85 | 0.016 | 0.015 |
| KEGG | mmu04612 | Antigen processing and presentation | 8/169 | 91/8910 | 3.17 | 0.020 | 0.019 |
| KEGG | mmu05133 | Pertussis | 7/169 | 77/8910 | 6.15 | 0.031 | 0.029 |
Figure 4GSEA analysis of transcriptomic profile between the ICH group and control group. (a) A rank of top 20 significantly enriched gene sets with their ES. (b) A panel of immune-related gene sets represented with enplots and heatmaps of related gene expression.
Figure 5Integrative analysis of transcriptomics and proteomics datasets. (a) Venn diagram of relationship between genes and proteins. (b) Pearson's correlation analysis of the expression of comolecules. The green spots represent differentially expressed proteins in the ICH group when compared with the controls, and the blue spots represent not differentially expressed proteins in the ICH group when compared with the controls. (c) Heatmap of the expression of comolecules between transcriptomics and proteomics datasets. (d) PPI network of 62 comolecules. The node size indicates the combined score, and the nodes color indicate the log2|FC| (red: high log2|FC| value, yellow: low log2|FC| value). (e) Identification of hub molecules derived from PPI network of 62 comolecules. (f) rCCA network between DEG and DEP datasets. The green triangle indicates mRNAs, and the yellow circle indicates proteins.
Biological processes involved in cluster 1 and cluster 2.
| GO term (biological process) |
| Corrected | Cluster frequency | Genes | |
|---|---|---|---|---|---|
| Network 1 | Sphingolipid catabolic process | 6.99 | 1.57 | 2/28, 7.1% | GALC, SMPDL3B |
| Membrane lipid catabolic process | 8.15 | 1.57 | 2/28, 7.1% | GALC, SMPDL3B | |
| Cerebellar cortex morphogenesis | 1.37 | 1.57 | 2/28, 7.1% | AGTPBP1, SERPINE2 | |
| Neurotransmitter metabolic process | 1.69 | 1.57 | 2/28, 7.1% | AGTPBP1, TH | |
| Cerebellum morphogenesis | 2.25 | 1.57 | 2/28, 7.1% | AGTPBP1, SERPINE2 | |
| Network 2 | Response to wounding | 4.76 | 6.15 | 6/20, 30.0% | APOH, SERPING1, SERPINA3N, CFP, CXCL3, AQP1 |
| Response to stress | 6.77 | 1.81 | 7/20, 35.0% | ANXA1, APOH, SERPING1, SERPINA3N, CFP, CXCL3, AQP1 | |
| Inflammatory response | 9.49 | 1.81 | 4/20, 20.0% | SERPING1, SERPINA3N, CFP, CXCL3 | |
| Acute inflammatory response | 2.04 | 1.81 | 3/20, 15.0% | SERPING1, SERPINA3N, CFP | |
| Response to stimulus | 2.04 | 1.81 | 9/20, 45.0% | ANXA1, ARG1, APOH, SERPING1, SERPINA3N, CFP, CXCL3, XDH, AQP1 |
GO: gene ontology.
Figure 6Validation of ten hub genes by qRT-qPCR. qRT-qPCR established that expression of following genes were upregulated in ICH vs. control brains of mice: Lyz2, C3, Serpina3n, Cfp, Ppbp, Haptoglobin, Serping1, Ctss, Itgb2, and Anxa2 in the ICH and control groups. n = 6 per group. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
Figure 7Validation of four candidates by Western blot and the correlation analysis between four candidates and behavior tests. (a) Representative Western blot bands and quantitative analysis of Itgb2, Serpina3n, Serping1, and Ctss protein expression. (b) Spearman's correlation analysis results showing the correlation between the protein expression levels of candidates and the scores of mGarcia test. (c) Spearman's correlation analysis results showing the correlation between the protein expression levels of candidates and the scores of beam walking test. n = 6 per group. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
Figure 8Predictive efficacy of SERPINA3N in diagnosis and prognosis in ICH patients. (a) Dot plots with plasma SERPINA3 levels in ICH patients and the controls. (b) Dot plots with plasma SERPINA3 levels between patients with good outcome and patients with poor outcome. (c) ROC curves of plasma SERPINA3 levels for prediction of 90-day prognosis of ICH patients. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.